
WilmerHale Represents Trevi Therapeutics in Securing \$50M in Series C Financing

JULY 24, 2017

Trevi Therapeutics, Inc. announced that they have completed a Series C financing of \$50.5 million led by New Enterprise Associates. The company plans to use the proceeds from the financing to advance the development of Nalbuphine® ER, a drug with a dual agonist/antagonist mechanism of action uniquely suited to treating itch associated in various dermatologic, metabolic, hematologic, and neuropathic conditions.

The WilmerHale deal team counseling Trevi Therapeutics was led by [Stuart Falber](#) and included [Sam Rothberg](#) and [Cara Fonseca](#).

Read [Trevi Therapeutics' press release](#) for more information.